COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
Anti-Inflammatory Agents
/ therapeutic use
Antirheumatic Agents
/ therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections
/ drug therapy
Cytokines
/ immunology
Drug Repositioning
Humans
Immune System
Immunity, Cellular
Immunosuppressive Agents
/ therapeutic use
Pandemics
Pneumonia, Viral
/ drug therapy
SARS-CoV-2
COVID-19
cytokine storm
inflammation
rheumatology
treatment
antiinflammatory
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
15
04
2020
accepted:
16
04
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines “cytokine storm” leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.
Identifiants
pubmed: 32299202
doi: 10.3906/sag-2004-168
pmc: PMC7195984
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antirheumatic Agents
0
Cytokines
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
620-632Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Références
J Antimicrob Chemother. 2015;70(6):1608-21
pubmed: 25693996
Virology. 2011 Nov 25;420(2):106-16
pubmed: 21959016
Science. 1996 Jan 12;271(5246):173-8
pubmed: 8539616
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43-i54
pubmed: 30806709
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
J Biol Chem. 1992 Dec 25;267(36):25744-7
pubmed: 1464591
Rheumatology (Oxford). 2007 May;46(5):808-10
pubmed: 17202178
J Virol. 2004 Jun;78(11):5642-50
pubmed: 15140961
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Infect Dis. 2020 Oct 1;222(9):1444-1451
pubmed: 32601708
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
PLoS Pathog. 2014 May 01;10(5):e1004077
pubmed: 24788150
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Intensive Care Med. 2020 Feb;46(2):315-328
pubmed: 32040667
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Crit Care. 2020 May 19;24(1):241
pubmed: 32430057
Sci China C Life Sci. 2009 May;52(5):464-9
pubmed: 19471869
Antiviral Res. 2018 Jan;149:143-149
pubmed: 29175128
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Viruses. 2012 May;4(5):833-46
pubmed: 22754651
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Antivir Ther. 2006;11(8):1021-30
pubmed: 17302372
Chest. 2020 Jul;158(1):55-56
pubmed: 32243944
Virology. 2015 Nov;485:330-9
pubmed: 26331680
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
Lancet. 2020 May 2;395(10234):1407-1409
pubmed: 32278362
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Antiviral Res. 2015 Mar;115:21-38
pubmed: 25554382
Front Microbiol. 2019 Jan 29;10:50
pubmed: 30761102
J Virol. 2009 Jul;83(14):7221-34
pubmed: 19420077
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Hellenic J Cardiol. 2020 Jan - Feb;61(1):42-45
pubmed: 32251729
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208
pubmed: 32164089
Virus Genes. 2011 Feb;42(1):37-45
pubmed: 20976535
J Infect Dis. 2004 Feb 15;189(4):648-51
pubmed: 14767818
Viruses. 2010 Aug;2(8):1804-1820
pubmed: 21994708
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
Reumatismo. 2015 Dec 30;67(3):849
pubmed: 26876193
J Gen Virol. 2000 Apr;81(Pt 4):853-79
pubmed: 10725411
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180
pubmed: 32207680
Crit Care Med. 1997 Jul;25(7):1115-24
pubmed: 9233735
Med J Aust. 2020 May;212(9):416-420
pubmed: 32266987
J Biol Regul Homeost Agents. 2020 Mar 31;34(2):333-338
pubmed: 32228825
Pathogens. 2020 Mar 04;9(3):
pubmed: 32143502
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
Adv Virus Res. 2006;66:193-292
pubmed: 16877062
Viruses. 2015 Apr 03;7(4):1700-25
pubmed: 25855243
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Lancet. 2014 Apr 26;383(9927):1503-1516
pubmed: 24290661
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
J Struct Biol. 2011 Apr;174(1):11-22
pubmed: 21130884
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Ecancermedicalscience. 2020 Mar 27;14:1022
pubmed: 32256705
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
Virusdisease. 2020 Mar;31(1):13-21
pubmed: 32206694
Natl Sci Rev. 2020 Jun;7(6):1012-1023
pubmed: 34676127
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:320-327
pubmed: 29207305
Ann Rheum Dis. 2020 May;79(5):668-669
pubmed: 32241792
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Signal Transduct Target Ther. 2020 Feb 21;5(1):18
pubmed: 32296012
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
BMC Infect Dis. 2016 Apr 21;16:174
pubmed: 27097824
J Virol. 2005 May;79(9):5288-95
pubmed: 15827143
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Xenobiotica. 1988 Apr;18(4):459-70
pubmed: 3135672
Immunopharmacol Immunotoxicol. 2013 Jun;35(3):434-42
pubmed: 23635029
J Blood Med. 2014 Jun 12;5:69-86
pubmed: 24966707
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
Virology. 2005 Apr 10;334(2):306-18
pubmed: 15780881
Microorganisms. 2020 Jan 08;8(1):
pubmed: 31936284
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Expert Opin Investig Drugs. 2019 Jul;28(7):573-581
pubmed: 31208237
BioDrugs. 2019 Feb;33(1):15-32
pubmed: 30701418
J Biomed Sci. 2006 Jan;13(1):59-72
pubmed: 16228284
Trends Microbiol. 2017 Jan;25(1):35-48
pubmed: 27743750
Cell Mol Immunol. 2020 Jul;17(7):765-767
pubmed: 32047258
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Oncology. 2020;98(3):131-137
pubmed: 31958792